Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.SELB · Entity 6015 | CFO, Treas. & Hd Corp Strategy | June 15, 2018 | June 19, 2018 |
| IPI Legacy Liquidation CoIMPL · Entity 15659 | Chief Fin. & Business Officer | February 14, 2023 | February 16, 2023 |
| Traws Pharma, Inc.TRAW · Entity 8032 | Director | July 09, 2026 | July 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date June 15, 2018 · Filed June 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.75 · Expires 2028-06-14 | Direct | 50,000 |
Reported balance
After 2018-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-15 · Grant · Acquired 50,000 · Balance 50,000 F1: The option will vest as to 25% of the shares on June 15, 2019. The remainder of the shares will vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest as to 25% of the shares on June 15, 2019. The remainder of the shares will vest in 36 equal monthly installments thereafter.
IPI Legacy Liquidation Co
Report date February 14, 2023 · Filed February 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2033-02-13 | Direct | 70,000 |
Reported balance
After 2023-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-14 · Grant · Acquired 70,000 · Balance 70,000 F1: The option vests as to 2.0833% of the total shares on March 14, 2023 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on February 14, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 2.0833% of the total shares on March 14, 2023 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on February 14, 2027, subject to the reporting person's provision of service to the issuer on each vesting date.
Traws Pharma, Inc.
Report date July 09, 2026 · Filed July 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2036-07-09 | Direct | 14,150 |
Reported balance
After 2026-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-09 · Grant · Acquired 14,150 · Balance 14,150 F1: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 15, 2026 00:19 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to buy) · Derivative | 14,150 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001586657-26-000003 · form4-07152026_120728.xml · derivative · entry 1 Leaman John Harold · CIK 0001586657 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,150 Underlying: Common Stock · 14,150 shares Expires 2036-07-09 F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Read SEC document |
| March 08, 2026 Filed Mar 10, 2026 23:20 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to buy) · Derivative | 33,435 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001586657-26-000002 · form4-03102026_110339.xml · derivative · entry 1 Leaman John Harold · CIK 0001586657 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,435 Underlying: Common Stock · 33,435 shares Expires 2036-03-08 F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:23 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 16,234 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001586657-25-000008 · form4-12162025_111250.xml · derivative · entry 2 Leaman John Harold · CIK 0001586657 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,234 Underlying: Common Stock · 16,234 shares Expires 2035-12-12 F2 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:23 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantCommon Stock | 4,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001586657-25-000008 · form4-12162025_111250.xml · nonDerivative · entry 1 Leaman John Harold · CIK 0001586657 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,058 F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 23:53 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 12,770 | $0.00 Strike: $2.31 | $0.00 |
DisclosureSEC source: 0001586657-25-000007 · form4-11252025_111110.xml · derivative · entry 1 Leaman John Harold · CIK 0001586657 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,770 Underlying: Common Stock · 12,770 shares Expires 2035-11-21 F1 · derivative.exercise_date: These options vest over three years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary. Read SEC document |
| October 01, 2025 Filed Oct 14, 2025 23:03 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 15,609 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001586657-25-000005 · form4-10142025_111013.xml · derivative · entry 1 Leaman John Harold · CIK 0001586657 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,609 Underlying: Common Stock · 15,609 shares Expires 2035-10-01 F1 · derivative.exercise_date: These options vest over three years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 18:20 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001209191-23-010245 · doc4.xml · derivative · entry 1 Leaman John Harold · CIK 0001586657 · Chief Fin. & Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2033-02-13 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares on March 14, 2023 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on February 14, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 18:46 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 10,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001365 · doc4.xml · derivative · entry 3 Leaman John Harold · CIK 0001586657 · Chief Fin. & Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,571 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 100% of the total shares on December 31, 2022, subject to the Reporting Person's continuation of employment on such vesting date. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 18:46 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | Tax withholdingCommon Stock | 3,627 | $3.75 | $13,601.25 |
DisclosureSEC source: 0001209191-23-001365 · doc4.xml · nonDerivative · entry 2 Leaman John Harold · CIK 0001586657 · Chief Fin. & Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,944 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the restricted stock units ("RSUs") and does not represent a sale by the reporting person. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 18:46 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | Exercise / conversionCommon Stock | 10,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001365 · doc4.xml · nonDerivative · entry 1 Leaman John Harold · CIK 0001586657 · Chief Fin. & Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 17:04 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $9.85 | $0.00 |
DisclosureSEC source: 0001209191-22-005450 · doc4.xml · derivative · entry 1 Leaman John Harold · CIK 0001586657 · Chief Fin. & Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares on February 26, 2022 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on January 26, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 17:31 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantRestricted Stock Units (RSUs) · Derivative | 10,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-061281 · doc4.xml · derivative · entry 1 Leaman John Harold · CIK 0001586657 · Chief Fin. & Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,571 Underlying: Common Stock · 10,571 shares Expires 2031-10-19 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs vest as to 100% of the total shares on December 31, 2022, subject to the reporting person's continuation of employment on such vesting date. Read SEC document |
| July 20, 2021 Filed Jul 26, 2021 18:00 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $12.16 | $0.00 |
DisclosureSEC source: 0001209191-21-048219 · doc4.xml · derivative · entry 1 Leaman John Harold · CIK 0001586657 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-07-19 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares on August 22, 2021 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on July 22, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 23:05 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001638599-18-000677 · doc4_5480.xml · derivative · entry 1 Leaman John Harold · CIK 0001586657 · CFO, Treas. & Hd Corp Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on June 15, 2019. The remainder of the shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 21:10 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (right to buy) · Derivative | 220,000 | $0.00 Strike: $10.23 | $0.00 |
DisclosureSEC source: 0001638599-17-001156 · doc4_5081.xml · derivative · entry 1 Leaman John Harold · CIK 0001586657 · CFO, Treas. & Hd Corp Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2027-11-16 F1 · derivative.exercise_date: This option vests as to 25% of the shares on October 26, 2018. The remainder of the shares will vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.